AB&B Bio-Tech Reports No Change in Share Capital for May 2026; Confirms Public Float Compliance

Bulletin Express06-04

AB&B Bio-Tech (H shares listed under stock code 02627) released its Monthly Return for Equity Issuer, confirming that total authorised capital and issued share structure remained unchanged in May 2026.

The company’s authorised share capital stayed at RMB 393.44 million, comprising 296.36 million H shares and 97.08 million domestic shares, each with a par value of RMB 1.

Issued share capital also showed no movement during the month. The number of issued H shares (excluding treasury shares) held steady at 296.36 million, and domestic shares at 97.08 million. No treasury shares were outstanding.

AB&B Bio-Tech reported no activity in share options, warrants, convertibles, or other equity-linked instruments, indicating no dilution or repurchase actions in the period.

The company confirmed compliance with the Hong Kong Stock Exchange’s minimum 25% public-float requirement for its H shares as at 31 May 2026.

The Monthly Return was submitted on 4 June 2026 and signed by Executive Director Li Runxiang.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1199640264?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-04 17:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199640264","market":"hk","top_or_hot":-1,"title":"AB&B Bio-Tech Reports No Change in Share Capital for May 2026; Confirms Public Float Compliance","media":"Bulletin Express","content":"<p>AB&B Bio-Tech (H shares listed under stock code 02627) released its Monthly Return for Equity Issuer, confirming that total authorised capital and issued share structure remained unchanged in May 2026.</p>\n<p>The company’s authorised share capital stayed at RMB 393.44 million, comprising 296.36 million H shares and 97.08 million domestic shares, each with a par value of RMB 1.</p>\n<p>Issued share capital also showed no movement during the month. The number of issued H shares (excluding treasury shares) held steady at 296.36 million, and domestic shares at 97.08 million. No treasury shares were outstanding.</p>\n<p>AB&B Bio-Tech reported no activity in share options, warrants, convertibles, or other equity-linked instruments, indicating no dilution or repurchase actions in the period.</p>\n<p>The company confirmed compliance with the Hong Kong Stock Exchange’s minimum 25% public-float requirement for its H shares as at 31 May 2026.</p>\n<p>The Monthly Return was submitted on 4 June 2026 and signed by Executive Director Li Runxiang.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AB&B Bio-Tech Reports No Change in Share Capital for May 2026; Confirms Public Float Compliance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAB&B Bio-Tech Reports No Change in Share Capital for May 2026; Confirms Public Float Compliance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-04 17:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AB&B Bio-Tech (H shares listed under stock code 02627) released its Monthly Return for Equity Issuer, confirming that total authorised capital and issued share structure remained unchanged in May 2026.</p>\n<p>The company’s authorised share capital stayed at RMB 393.44 million, comprising 296.36 million H shares and 97.08 million domestic shares, each with a par value of RMB 1.</p>\n<p>Issued share capital also showed no movement during the month. The number of issued H shares (excluding treasury shares) held steady at 296.36 million, and domestic shares at 97.08 million. No treasury shares were outstanding.</p>\n<p>AB&B Bio-Tech reported no activity in share options, warrants, convertibles, or other equity-linked instruments, indicating no dilution or repurchase actions in the period.</p>\n<p>The company confirmed compliance with the Hong Kong Stock Exchange’s minimum 25% public-float requirement for its H shares as at 31 May 2026.</p>\n<p>The Monthly Return was submitted on 4 June 2026 and signed by Executive Director Li Runxiang.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02627","symbol_name":"中慧生物-B","start_time":0,"source_url":"","article_id":"1199640264","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199640264","pubTimestamp":1780565017,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"AB&B Bio-Tech (H shares listed under stock code 02627) released its Monthly Return for Equity Issuer, confirming that total authorised capital and issued share structure remained unchanged in May...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02627":"中慧生物-B"},"translate_title":"AB&B Bio-Tech报告2026年5月股本没有变化；确认公众持股量合规","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02627":1},"content_text":"AB&B Bio-Tech (H shares listed under stock code 02627) released its Monthly Return for Equity Issuer, confirming that total authorised capital and issued share structure remained unchanged in May 2026.\nThe company’s authorised share capital stayed at RMB 393.44 million, comprising 296.36 million H shares and 97.08 million domestic shares, each with a par value of RMB 1.\nIssued share capital also showed no movement during the month. The number of issued H shares (excluding treasury shares) held steady at 296.36 million, and domestic shares at 97.08 million. No treasury shares were outstanding.\nAB&B Bio-Tech reported no activity in share options, warrants, convertibles, or other equity-linked instruments, indicating no dilution or repurchase actions in the period.\nThe company confirmed compliance with the Hong Kong Stock Exchange’s minimum 25% public-float requirement for its H shares as at 31 May 2026.\nThe Monthly Return was submitted on 4 June 2026 and signed by Executive Director Li Runxiang.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1199640264","isCrawlerRequest":true}